-
Aeterna Zentaris Announces Completion of Patient Recruitment for Phase 3 Trial with Perifosine in Refractory Advanced Colorectal Cancer
Wednesday, July 27, 2011 - 8:36am | 103Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer. The trial, involving over 430 patients, is being conducted pursuant to a Special Protocol Assessment with the Food and...
-
Piper Jaffray Rates CPHD
Wednesday, July 27, 2011 - 8:22am | 28According to Piper Jaffray, Cepheid (NASDAQ: CPHD), PT is set to $39 and are rated as Overweight. Cepheid closed yesterday at $39.48.
-
UPDATE: Oppenheimer Raises PT on Gilead Sciences to $46
Wednesday, July 27, 2011 - 7:26am | 111Oppenheimer is out with its report today on Gilead Sciences (NASDAQ: GILD), raising its PT from $45 to $46. In a note to clients, Oppenheimer writes, "With regard to new fixed-dose combinations, GILD is preparing for the Btripla launch and we expect US/EU approvals in 2H11. More importantly, we...
-
JP Morgan Raises PT on Gilead Sciences To $50
Wednesday, July 27, 2011 - 7:14am | 27JP Morgan has raised the price target on Gilead Sciences (NASDAQ: GILD) from $45 to $50 and maintains its Overweight rating.
-
Oppenheimer Raises PT On Gilead Sciences To $46
Wednesday, July 27, 2011 - 6:12am | 26Oppenheimer has raised the price target on Gilead Sciences (NASDAQ: GILD) from $45 to $46 and maintains its Outperform rating.
-
Stocks to Watch for Wednesday 7/27/2011: Fresh 52 Week Highs and Lows
Wednesday, July 27, 2011 - 4:37am | 2249Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Tuesday's trading session (listed from highest total volume to...
-
ISI Provides Color on Gilead Sciences
Wednesday, July 27, 2011 - 3:02am | 142ISI provided color on Gilead Sciences (NASDAQ: GILD). In a research report published today, the rating agency commented on the company's HIV drug. In the report, ISI states, “What's interesting to us is that number of patients on GILD HIV drugs in the EU hasn't really grown. This is despite...
-
Playing Chicken 07-26-2011
Tuesday, July 26, 2011 - 6:46pm | 1029Cusick's Corner We finished right on the lows and the bureaucrats in Washington still think that it is ok to continue to play Deficit Chicken. The pullback in the Buck was something that caught my eye and explained the run in the Commodities, XLE/DBC/FCX, so these are the sectors that investment...
-
CytRx Announces Public Offering; No Amount Given
Tuesday, July 26, 2011 - 4:34pm | 66CytRx Corporation (Nasdaq: CYTR) today announced that it intends to offer shares of its common stock and common stock purchase warrants in an underwritten public offering. Cowen and Company, LLC and Roth Capital Partners, LLC are acting as the underwriters of the offering. All of the shares and...
-
C.K. Cooper Reiterates Ligand Pharmaceuticals Buy, Raises PT
Tuesday, July 26, 2011 - 2:53pm | 113C.K. Cooper reiterated its Ligand Pharmaceuticals (NASDAQ: LGND) Buy rating increased its Ligand price target from $21 to $24 in a research report published today. In the report, C.K. Cooper states, "We reiterate our BUY rating and are increasing our price target from $21.00 to $24.00 as a result...
-
Pharma News; BioSante Pharmaceuticals Reports Second Quarter 2011 Financial Results
Tuesday, July 26, 2011 - 1:48pm | 520LINCOLNSHIRE, Ill. - July 26, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its financial results for the second quarter of 2011. The Company's cash and cash equivalents as of June 30, 2011 were approximately $37.1 million. BioSante incurred a...
-
Aeterna Zentaris Completes Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency
Tuesday, July 26, 2011 - 1:31pm | 83Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency. The Company is currently proceeding with detailed analyses of the data and preparing for a pre-New Drug Application meeting...
-
Amgen Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter
Tuesday, July 26, 2011 - 12:29pm | 562Amgen (NASDAQ: AMGN) unveils its next round of earnings this Friday, July 29, 2011. Here's Benzinga's advanced look at Amgen's second quarter earnings report. Earnings and Revenue: Wall Street expects an EPS of $1.30 per share and revenues of $3.78 billion. Amgen's latest numbers will no...
-
Tuesday's Put/Call Ratio Leaders
Tuesday, July 26, 2011 - 12:28pm | 77Here are today's Put/Call Ratio leaders… 1. Incyte Corp. (NASDAQ: INCY) 3,542 puts, 152 calls 2. EOG Resources (NYSE: EOG) 5,943 puts, 265 calls 3. Barclays Bank (NYSE: BCS) 12,613 puts, 709 calls 4. Boyd Gaming (NYSE: BYD) 9,744 puts, 618 calls 5. Waste Management (NYSE: WM) 4,629 puts, 302 calls...
-
Chelsea Therapeutics Announces Preliminary Data From Exploratory Phase II Study Demonstrates Significant Activity of Droxidopa in Adult Attention Deficit Hyperactivity Disorder
Tuesday, July 26, 2011 - 8:39am | 88Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) announced positive top-line results of an investigator-led Phase II clinical study of droxidopa in combination with carbidopa in adults with attention deficit hyperactivity disorder. The single-center, 12-week study enrolled 20 patients...